We are delighted to announce Dr Simon Aspland has accepted an invitation by Isomerase to join the company as CEO from July 2023 to help move us into the next successful chapter of the business. Cofounder Dr Matt Gregory has decided to move from CEO to provide strong scientific leadership as Chief Scientific Officer (CSO) and concentrate on his passion for strengthening the company’s underlying scientific foundation whilst cofounder Dr Steven Moss will continue to lead in his vital role as Chief Technology Officer (CTO). Matt and Steven remain on the board along with Prof Barrie Wilkinson and Rob Booth. Further, we would like to express our gratitude to Dr Steve Martin who will be leaving his role as Chief Business Officer after 7 years to pursue new opportunities.
Simon joins Isomerase from his current role as Head of Commercialisation since 2019 at the John Innes Centre (JIC), Norwich, where he has led on expanding contract research, supporting spinouts, and leveraging intellectual property rights in the field of health, sustainability and agriculture. Simon brings over 20 years of experience in the USA and UK in biotechnology and he has cofounded, developed and held senior management positions within a host of innovative businesses including as cofounder and CEO of Chalante, VP of Business Development at Acidophil and cofounder and VP of Business Development at Agrimetis, all three past clients of Isomerase.
Dr Matt Gregory commented “It has been an honour and a privilege to help lead Isomerase since we founded the company in 2012. I am immensely proud of what we have achieved in that time, growing from just three staff in 2013 to a company with two sites and a staff of 35 colleagues. We have managed to do this by growing organically, without requiring external investment and whilst maintaining year-on-year profitability and supporting a wide range of clients with top quality science.” He continued “However, the company has grown to a point where it makes sense for me to focus on solidifying and growing the scientific capability, whilst a more commercially focussed CEO, with fresh energy and vision takes over the reins of the business. We are very excited to bring him into the team and for him to lead the next phase in the growth of Isomerase. After spending the last 12 months looking at options, we are pleased to announce that Simon will take on the role of CEO, he is an excellent fit with our company’s values and vision, and we look forward to working with him."
Dr Gregory added “Steve Martin joined the company back in 2016 and has been invaluable in helping grow the company to where we are today. We are all very grateful for the excellent job he has done and wish him the very best for the future. From expanding our network of clients and partners, to leading our business team, Steve has been an incredible asset at Isomerase. We all wish him the best for the future.”
Dr Simon Aspland concluded "I have worked with Isomerase from shortly after its formation and I have been impressed with its team culture, entrepreneurship, talent, creativity, reliability, and expertise as it has continued to create value for clients. Throughout the time I have known them, I have admired the integrity and passion Matt, Steven and other Isomerase colleagues bring to their work. I am honoured and excited to join and lead the Isomerase team and I believe that my experience and abilities will build value in the business, as they continue to help address global challenges in sustainability and human health.